BioXcel Therapeutics (NASDAQ:BTAI) Releases Quarterly Earnings Results, Misses Estimates By $0.19 EPS

BioXcel Therapeutics (NASDAQ:BTAI) posted its quarterly earnings data on Sunday. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.19), MarketWatch Earnings reports.

Shares of NASDAQ:BTAI traded up $2.60 during midday trading on Tuesday, reaching $33.00. 453,291 shares of the company’s stock traded hands, compared to its average volume of 527,131. BioXcel Therapeutics has a 1 year low of $28.00 and a 1 year high of $71.50. The company has a market cap of $812.86 million, a P/E ratio of -9.81 and a beta of 1.31. The company has a fifty day simple moving average of $36.15 and a two-hundred day simple moving average of $46.65.

BTAI has been the topic of a number of recent research reports. Truist dropped their target price on BioXcel Therapeutics from $150.00 to $127.00 in a research report on Thursday, April 1st. Truist Securities dropped their target price on BioXcel Therapeutics from $150.00 to $127.00 and set a “buy” rating on the stock in a research report on Thursday, April 1st. Canaccord Genuity dropped their target price on BioXcel Therapeutics from $110.00 to $95.00 and set a “buy” rating on the stock in a research report on Thursday, April 1st. UBS Group initiated coverage on BioXcel Therapeutics in a research report on Monday, February 1st. They issued a “buy” rating and a $99.00 target price on the stock. Finally, Berenberg Bank initiated coverage on BioXcel Therapeutics in a research report on Thursday, April 15th. They issued a “buy” rating and a $75.00 target price on the stock. Eleven research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $101.36.

In other news, insider Vincent O’neill sold 25,000 shares of the stock in a transaction that occurred on Wednesday, February 17th. The stock was sold at an average price of $55.58, for a total transaction of $1,389,500.00. Following the transaction, the insider now owns 15,000 shares in the company, valued at approximately $833,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 9.40% of the company’s stock.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors.

Further Reading: Conference Calls and Individual Investors

Earnings History for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.